Elizabeth Y Chiao1, Susan E Krown. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
Abstract
PURPOSE OF REVIEW: Since the introduction of highly active antiretroviral therapy (HAART), the natural history of human immunodeficiency virus (HIV) infection has changed. Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epidemiologic studies showed that HIV-infected patients were at higher risk for developing specific AIDS-defining malignancies. More recent studies linking HIV/AIDS databases to cancer registries have shown that HIV-infected patients are also at higher risk of developing non-AIDS-defining malignancies. We review the most recent data regarding clinical presentation, pathology, and treatment outcomes for these non-AIDS-defining malignancies. RECENT FINDINGS: Recent large cohort studies linking HIV/AIDS databases to cancer registries have shown that HIV-infected patients are also at higher risk of developing non-AIDS-defining malignancies. Besides anal cancer and Hodgkin disease, the cohort studies have identified other malignancies that appear to occur at a higher rate in the HIV-infected population as compared with the general population. These malignancies include lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head and neck, conjunctival cancer, multiple myeloma, and leukemias. SUMMARY: As the epidemiology of non-AIDS-defining malignancies continues to evolve, it is unclear whether the appropriate treatments and outcomes for these or other malignancies are changed for HIV-infected patients treated with HAART.
PURPOSE OF REVIEW: Since the introduction of highly active antiretroviral therapy (HAART), the natural history of human immunodeficiency virus (HIV) infection has changed. Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epidemiologic studies showed that HIV-infectedpatients were at higher risk for developing specific AIDS-defining malignancies. More recent studies linking HIV/AIDS databases to cancer registries have shown that HIV-infectedpatients are also at higher risk of developing non-AIDS-defining malignancies. We review the most recent data regarding clinical presentation, pathology, and treatment outcomes for these non-AIDS-defining malignancies. RECENT FINDINGS: Recent large cohort studies linking HIV/AIDS databases to cancer registries have shown that HIV-infectedpatients are also at higher risk of developing non-AIDS-defining malignancies. Besides anal cancer and Hodgkin disease, the cohort studies have identified other malignancies that appear to occur at a higher rate in the HIV-infected population as compared with the general population. These malignancies include lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head and neck, conjunctival cancer, multiple myeloma, and leukemias. SUMMARY: As the epidemiology of non-AIDS-defining malignancies continues to evolve, it is unclear whether the appropriate treatments and outcomes for these or other malignancies are changed for HIV-infectedpatients treated with HAART.
Authors: Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell Journal: Am J Respir Cell Mol Biol Date: 2005-10-06 Impact factor: 6.914
Authors: Nir Wasserberg; Joseph W Nunoo-Mensah; Claudia Gonzalez-Ruiz; Robert W Beart; Andreas M Kaiser Journal: Int J Colorectal Dis Date: 2007-02-21 Impact factor: 2.571
Authors: John V Gahagan; Wissam J Halabi; Vinh Q Nguyen; Joseph C Carmichael; Alessio Pigazzi; Michael J Stamos; Steven D Mills Journal: J Gastrointest Surg Date: 2016-03-03 Impact factor: 3.452
Authors: Kathy Petoumenos; Eugenie Hui; Nagalingeswaran Kumarasamy; Stephen J Kerr; Jun Yong Choi; Yi-Ming A Chen; Tuti Merati; Fujie Zhang; Poh-Lian Lim; Somnuek Sungkanuparph; Sanjay Pujari; Sasheela Ponnampalavanar; Rosanna Ditangco; Christopher Kc Lee; Andrew Grulich; Matthew G Law Journal: J Int AIDS Soc Date: 2010-12-10 Impact factor: 5.396